What 4 Analyst Ratings Have To Say About Silence Therapeutics
Portfolio Pulse from Benzinga Insights
Four analysts have recently updated their ratings on Silence Therapeutics (NASDAQ:SLN), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $73.00, down from $75.00, with a high estimate of $75.00 and a low of $67.00. Silence Therapeutics, a biotech company, is working on therapies SLN360 and SLN124 for heart disease and anemia, respectively. Despite a strong net margin, the company has seen a revenue decline of -17.0% and has below-average ROE and impressive ROA.
March 13, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Silence Therapeutics has received mixed analyst ratings with a revised average price target of $73. The company's focus on therapies for heart disease and anemia, alongside a notable revenue decline and financial metrics, could influence its stock performance.
The mixed analyst ratings and revised price target reflect uncertainty and potential in Silence Therapeutics' future performance. The revenue decline is a concern, but the company's innovative therapies could offer long-term growth potential. The financial metrics indicate challenges but also areas of strength, such as net margin and ROA.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100